All In MedTech

Device Trial Radar · NCT07369180

NQ Square TMS for Major Depressive Disorder: One Day, Three Sessions in Adults

Safety and Efficacy of an Accelerated, Rectangular Waveform rTMS Protocol in Treatment of Adults With Major Depressive Disorder.

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Jan 15, 2026

Primary completion

Mar 9, 2026

Study completion Jun 18, 2026

Sponsor

Lead sponsor
NeuroQore Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 27, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transcranial Magnetic Stimulation (TMS) Therapy is a non-invasive procedure that uses magnetic pulses to stimulate the cortex (brain) to treat Major Depressive Disorder (MDD). Currently established therapy uses one 19-minute treatment session per day for 5 days per week for 6 weeks, for a total of 30 treatment sessions. The goal of this multi-site sham-controlled double-blinded randomized clinical trial is to evaluate the safety and effectiveness of accelerating the delivery of the NeuroQore Square TMS system's rectangular waveform rTMS protocol for the treatment of adults aged 22-85 with Major Depressive Disorder. The accelerated protocol of this study will involve the same currently FDA-cleared 19-min treatment session offered three times in a single day, with no additional treatment sessions.

Conditions

  • Major Depressive Disorder

Interventions

  • Active Accelerated rTMS TreatmentDevice

    1 Day x 3 Sessions of 19-minutes active rTMS treatment, with 60 minutes rest between sessions.

  • Sham Accelerated rTMS TreatmentDevice

    1 Day x 3 Sessions of 19-minutes sham rTMS treatment, with 60 minutes rest between sessions. It simulates the treatment regimen but blocks the treatment from reaching the target in Cortex.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline (treatment day, pre-treatment), immediately post-treatment, 24 hours, 7 days and 30 days post-treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • LGTC Group

    Campbell, California

  • LGTC Group

    Sunnyvale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.